Cargando…

The -159C/T polymorphism in the CD14 gene and cancer risk: a meta-analysis

PURPOSE: The -159C/T polymorphism in the cluster of differentiation (CD)14 gene has been extensively studied for an association with cancer; however, results from replication studies have been inconclusive. The aim of this study was to perform a comprehensive assessment of the possible association b...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Wei, Jia, Liuqun, Guo, Shujin, Hu, Qianjin, Shen, Yongchun, Li, Ningxiu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3865088/
https://www.ncbi.nlm.nih.gov/pubmed/24376358
http://dx.doi.org/10.2147/OTT.S54547
_version_ 1782295985985159168
author Zhou, Wei
Jia, Liuqun
Guo, Shujin
Hu, Qianjin
Shen, Yongchun
Li, Ningxiu
author_facet Zhou, Wei
Jia, Liuqun
Guo, Shujin
Hu, Qianjin
Shen, Yongchun
Li, Ningxiu
author_sort Zhou, Wei
collection PubMed
description PURPOSE: The -159C/T polymorphism in the cluster of differentiation (CD)14 gene has been extensively studied for an association with cancer; however, results from replication studies have been inconclusive. The aim of this study was to perform a comprehensive assessment of the possible association between the -159C/T polymorphism in the CD14 gene and cancer risk, by meta-analysis. METHODS: We searched in PubMed, Embase, and other databases, covering all case-control studies on the possible association between CD14 -159C/T gene polymorphism and cancer risk. Data were extracted and statistical analyses were performed using RevMan 5.0 and STATA 12.0 software. RESULTS: A total of 12 case-control studies met our inclusion criteria, including 2,498 cases and 2,696 controls. The combined analysis indicated that the CD14 -159C/T gene polymorphism didn’t confer risk for cancer – the recessive model (TT versus (vs) CT + CC), showed odds ratio (OR) =1.01, 95% confidence interval (CI) =0.82–1.23 (P=0.94), while the dominant model (TT + TC vs CC) showed OR =0.81, 95% CI =0.66–1.00 (P=0.05). A subgroup analysis by ethnicity showed that the cancer risk associated with CD14 -159C/T gene polymorphism was significantly decreased among Caucasians for the TC + TT vs CC comparison (OR =0.83, 95% CI =0.70–0.98 [P=0.03]). The subgroup analysis by cancer type suggested that the CD14 -159C/T gene polymorphism was not associated with gastric cancer risk. CONCLUSION: The evidence from the present meta-analysis did not support the CD14 -159C/T gene polymorphism as a genetic risk factor for cancer. Further studies on different cancer types and ethnicities are needed to validate our findings.
format Online
Article
Text
id pubmed-3865088
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-38650882013-12-27 The -159C/T polymorphism in the CD14 gene and cancer risk: a meta-analysis Zhou, Wei Jia, Liuqun Guo, Shujin Hu, Qianjin Shen, Yongchun Li, Ningxiu Onco Targets Ther Original Research PURPOSE: The -159C/T polymorphism in the cluster of differentiation (CD)14 gene has been extensively studied for an association with cancer; however, results from replication studies have been inconclusive. The aim of this study was to perform a comprehensive assessment of the possible association between the -159C/T polymorphism in the CD14 gene and cancer risk, by meta-analysis. METHODS: We searched in PubMed, Embase, and other databases, covering all case-control studies on the possible association between CD14 -159C/T gene polymorphism and cancer risk. Data were extracted and statistical analyses were performed using RevMan 5.0 and STATA 12.0 software. RESULTS: A total of 12 case-control studies met our inclusion criteria, including 2,498 cases and 2,696 controls. The combined analysis indicated that the CD14 -159C/T gene polymorphism didn’t confer risk for cancer – the recessive model (TT versus (vs) CT + CC), showed odds ratio (OR) =1.01, 95% confidence interval (CI) =0.82–1.23 (P=0.94), while the dominant model (TT + TC vs CC) showed OR =0.81, 95% CI =0.66–1.00 (P=0.05). A subgroup analysis by ethnicity showed that the cancer risk associated with CD14 -159C/T gene polymorphism was significantly decreased among Caucasians for the TC + TT vs CC comparison (OR =0.83, 95% CI =0.70–0.98 [P=0.03]). The subgroup analysis by cancer type suggested that the CD14 -159C/T gene polymorphism was not associated with gastric cancer risk. CONCLUSION: The evidence from the present meta-analysis did not support the CD14 -159C/T gene polymorphism as a genetic risk factor for cancer. Further studies on different cancer types and ethnicities are needed to validate our findings. Dove Medical Press 2013-12-10 /pmc/articles/PMC3865088/ /pubmed/24376358 http://dx.doi.org/10.2147/OTT.S54547 Text en © 2014 Zhou et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Zhou, Wei
Jia, Liuqun
Guo, Shujin
Hu, Qianjin
Shen, Yongchun
Li, Ningxiu
The -159C/T polymorphism in the CD14 gene and cancer risk: a meta-analysis
title The -159C/T polymorphism in the CD14 gene and cancer risk: a meta-analysis
title_full The -159C/T polymorphism in the CD14 gene and cancer risk: a meta-analysis
title_fullStr The -159C/T polymorphism in the CD14 gene and cancer risk: a meta-analysis
title_full_unstemmed The -159C/T polymorphism in the CD14 gene and cancer risk: a meta-analysis
title_short The -159C/T polymorphism in the CD14 gene and cancer risk: a meta-analysis
title_sort -159c/t polymorphism in the cd14 gene and cancer risk: a meta-analysis
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3865088/
https://www.ncbi.nlm.nih.gov/pubmed/24376358
http://dx.doi.org/10.2147/OTT.S54547
work_keys_str_mv AT zhouwei the159ctpolymorphisminthecd14geneandcancerriskametaanalysis
AT jialiuqun the159ctpolymorphisminthecd14geneandcancerriskametaanalysis
AT guoshujin the159ctpolymorphisminthecd14geneandcancerriskametaanalysis
AT huqianjin the159ctpolymorphisminthecd14geneandcancerriskametaanalysis
AT shenyongchun the159ctpolymorphisminthecd14geneandcancerriskametaanalysis
AT liningxiu the159ctpolymorphisminthecd14geneandcancerriskametaanalysis
AT zhouwei 159ctpolymorphisminthecd14geneandcancerriskametaanalysis
AT jialiuqun 159ctpolymorphisminthecd14geneandcancerriskametaanalysis
AT guoshujin 159ctpolymorphisminthecd14geneandcancerriskametaanalysis
AT huqianjin 159ctpolymorphisminthecd14geneandcancerriskametaanalysis
AT shenyongchun 159ctpolymorphisminthecd14geneandcancerriskametaanalysis
AT liningxiu 159ctpolymorphisminthecd14geneandcancerriskametaanalysis